News

AfBA logo

AfPA and Cancer Care Explore the Cancer Treatment Experience

  • FLASCO
  • September 16, 2016
  • News
  • No Comments

  Cancer patients may feel under-informed about their diagnosis, overwhelmed by out-of-pocket expenses and unable to carry out day-to-day activities – despite being confident about their quality of care. This narrative emerged during an August 9 webinar co-hosted by the Alliance for Patient Access and Cancer Care, which explored Cancer Care’s 2016 Patient Access & Engagement Report. The report included…

Cigna – JW Modifier Start Date Update

FLASCO recently contacted Cigna on behalf of our 2,000 plus members requesting that Cigna reconsider the start date for the JW Modifier. It was pointed out to Cigna that Medicare had pushed the implementation back to 1/1/17. This will allow practices to ensure appropriate IT resources are in place to report the waste appropriately. At…

Comprehensive Cancer Center at Broward Health Medical Center Named Affiliate Member of University of Florida for NRG Oncology

  • FLASCO
  • September 16, 2016
  • News
  • No Comments

The Comprehensive Cancer Center at Broward Health Medical Center (BHMC) has been granted Affiliate Membership by NRG Oncology – a non-profit research organization that conducts oncologic clinical research and broadly disseminates study results for informing clinical decision-making and healthcare policy. Broward Health North was also approved as an affiliate site. The membership grants BHMC the…

Suncoast Cancer Institute Goes Above and Beyond

  • FLASCO
  • September 16, 2016
  • News
  • No Comments

Suncoast Cancer Institute in Sarasota, FL founder, Dr. Penny Heinrich, and Amy Akins, BSN, RN, OCN, both diligently worked on a patient’s behalf in concert with Walgreen’s to facilitate a lower drug cost. A Tarceva patient originally filled a prescription and was told they would have a $2000 co-pay amount, that the patient was unable…

ASCO, SGO Update Guidelines On Role Of Chemo For Advanced Ovarian Cancer

  • FLASCO
  • September 16, 2016
  • News
  • No Comments

  All patients with stage IIIC or IV epithelial ovarian cancer associated with high clinical risk or a low likelihood of optimal surgical resection should receive neoadjuvant chemotherapy, according to a new clinical practice guideline. The recommendation pertains to women who have high-risk features such as older age or a high comorbidity burden or who…

foundation medicine

Foundation Medicine Launches Blood-Based Liquid Biopsy, FoundationACT

  Foundation Medicine has launched a new assay, FoundationACT (Assay for Circulating Tumor DNA), a rigorously validated and highly accurate blood-based circulating tumor DNA (ctDNA) assay that provides patients and oncologists with a new option for comprehensive genomic profiling when a tissue biopsy is not feasible or when tissue is not available. By analyzing cell-free…

Infusion Pump Billing Update

CMS recently provided additional clarification to MACs and providers regarding reimbursement for prolonged drug and biological infusions that are started in the office or outpatient hospital and are associated with care that is billed incident to a physician service using an external pump. In order for Medicare to pay for a drug or biological, the…

Genentech’s TECENTRIQ Upcoming Webinars

  • Amanda Bridges
  • September 15, 2016
  • e-Learning
  • No Comments

On behalf of Genentech, you are invited to attend one of three webcasts across two days that span lunch times across 3 time zones: Introducing TECENTRIQ: The First and Only FDA-Approved Anti-PDL1 Immunotherapy for Previously Treated Locally Advanced Metastatic Urothelial Carcinoma September 28, 2016 Fairooz Kabbinavar, MD – UCLA, Los Angeles, CA 3:00pm ET, 2:00pm…

ASCO Annual Meeting Collective Wisdom

  • Amanda Bridges
  • September 12, 2016
  • e-Learning
  • No Comments

Novartis Oncology is pleased to invite you to virtually attend sessions from the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. To access the virtual platform please register at www.asco2016.com/FLASCO to begin viewing the recorded video sessions in the single track of your choice and learn about the practice-changing advances in oncology presented at…

Sylvester Earns Lung Cancer Screening Center Designation by the American College of Radiology

  • Amanda Bridges
  • September 9, 2016
  • News
  • No Comments

The lung cancer screening program at Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, has been designated an American College of Radiology (ACR) Lung Cancer Screening Center. The voluntary designation signifies that the program and protocol meet the requirements set forth by the ACR lung cancer screening committee. It…

US Oncology logo

Woodlands Medical Specialists Joins The US Oncology Network

  • Amanda Bridges
  • September 6, 2016
  • News
  • No Comments

Union strengthens Woodlands’ ability to remain independent, providing access to vast resources Pensacola, Florida (September 6, 2016) – Woodlands Medical Specialists, a physician-owned multi-specialty outpatient clinic serving Florida’s Panhandle region, has joined The US Oncology Network. The Network provides strong and comprehensive practice management capabilities and value-based care expertise that are critical for large practices…

Dr. Ayman Barakat Joins Florida Cancer Specialists in Hernando County

  • Amanda Bridges
  • August 17, 2016
  • News
  • No Comments

Spring Hill, FL – August 16, 2016. . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Ayman Barakat, MD has joined the practice and is seeing patients at two FCS locations in Hernando County, FL. Dr. Barakat will practice at the Brooksville…

BUCCANEERS AND FLORIDA CANCER SPECIALISTS RENEW PARTNERSHIP

  • Amanda Bridges
  • August 12, 2016
  • News
  • No Comments

Tampa, FL – August 10, 2016……… The Tampa Bay Buccaneers and Florida Cancer Specialists & Research Institute (FCS) announced that they have renewed their partnership with a multi-year deal. The work being performed by Florida Cancer Specialists & Research Institute (FCS)in the research and treatment of cancer is making a real difference in the lives…

NCCN Guidelines Updated

  • FLASCO
  • August 11, 2016
  • News
  • No Comments

NCCN has published NEW NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™ for the following disease type: Testicular Cancer, Version 2.2016 NCCN has published updates to the NCCN Guidelines® and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Small Cell Lung Cancer. These NCCN Guidelines are currently available as Version 1.2017.  Adjuvant…

NCCN has published updates to the NCCN Guidelines for Breast Cancer Screening and Diagnosis.

  • FLASCO
  • August 8, 2016
  • News
  • No Comments

NCCN has published updates to the NCCN Guidelines for Breast Cancer Screening and Diagnosis. These NCCN Guidelines are currently available as Version 1.2016.  “Clinical Breast Exam” was changed to “Clinical Encounter” with the footnote stating, “Clinical encounter should encompass ongoing risk assessment, risk reduction counseling, as well as a clinical breast exam.” (BSCR-1) “Consider tomosynthesis” is a…

NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Central Nervous System Cancers. These NCCN Guidelines are currently available as Version 1.2016.

  • FLASCO
  • August 8, 2016
  • News
  • No Comments

NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Central Nervous System Cancers. These NCCN Guidelines are currently available as Version 1.2016.   Anaplastic Gliomas (GLIO-2) The following adjuvant treatment option has been removed for 1p19q codeleted anaplastic oligodendroglioma/anaplastic oligoastrocytoma: PCV or temozolomide chemotherapy (category 2B). Glioblastoma…

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Cancer-Associated Venous Thromboembolic Disease. These NCCN Guidelines® are currently available as Version 1.2016.

  • FLASCO
  • August 8, 2016
  • News
  • No Comments

Venous Thromboembolism Prophylaxis VTE Prophylaxis Following Discharge and for Ambulatory Cancer Patients at Risk (VTE-2) For medical oncology patients in other outpatient settings (ie, those without multiple myeloma), the following footnote was removed: “Consider patient conversation about risks and benefits of VTE prophylaxis in patients with a Khorana score ≥3. (See Khorana Predictive Model [VTE-A…

NCCN has published updates to the NCCN Guidelines and Chemo Order Templates

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Melanoma. These NCCN Guidelines® are currently available as Version 3.2016.  Imaging recommendations were clarified, including the following: Addition of footnote “i”, specifying modalities wherever imaging is mentioned: “Chest/abdominal/pelvic CT with contrast, brain MRI with contrast, and/or FDG PET/CT. Neck CT with…

New Executive Medical Director at Florida Hospital

  • FLASCO
  • July 13, 2016
  • News
  • No Comments

Mark A. Socinski, MD, has been appointed Executive Medical Director of the Florida Hospital Cancer Institute. In his role, he will oversee the coordination of clinical cancer services for the Florida Hospital network. He will also be an active member of the Institute’s Thoracic Oncology Program. Dr. Socinski has spent more than 20 years in…

The FLASCO Mobile App is Here!

  • Amanda Bridges
  • July 10, 2016
  • News
  • No Comments

FLASCO has launched a mobile app that provides members with an easy-to-access resource featuring clinical and drug updates, information on FLASCO events, a job board, forums, directory of members, podcasts, e-learning tools and more! The app is free and can be download in iTunes or in the Google Play Store. Some content is protected for…

Insys Therapeutics Announces FDA Approval of Syndros™

Insys Therapeutics, Inc. (“Insys” or “the Company”) (INSY) today announced that the U.S. Food and Drug Administration (FDA) has approved Insys’ dronabinol oral solution, SyndrosTM, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol (“THC”). Syndros is approved for use in treating anorexia associated with weight loss in patients…

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer. These NCCN Guidelines® are currently available as Version 1.2016.  ·         For patients with a suspicious palpable mass and/or symptoms, the following primary treatment option has been revised: “Patients with bulky stage III/IV who are poor surgical candidates due…

HHS Announces Physician Groups Selected for an Initiative Promoting Better Cancer Care

  • FLASCO
  • June 29, 2016
  • News
  • No Comments

HHS Oncology Care Model attracts almost twice the expected number of physician group practices The U.S. Department of Health and Human Services (HHS) today announced that it has selected nearly 200 physician group practices and 17 health insurance companies to participate in a care delivery model that supports and encourages higher quality and more coordinated…

Florida Physician Assistant Update:

  • FLASCO
  • June 27, 2016
  • News
  • No Comments

Governor Scott signed HB 375 into law on Monday, March 28, 2016.  It relates to Physician Assistants (PA) and includes the following changes to the law: At renewal, PA must acknowledge that he/she has completed a minimum of ten (10) hours continuing medical education in the specialty practice in which the PA has prescriptive privileges….

Vote Now! Dr. Lichter Nominated for Modern Healthcare’s List of 100 Most Influential People in Healthcare

  • FLASCO
  • June 22, 2016
  • News
  • No Comments

ASCO’s CEO, and FLASCO member, Dr. Allen Lichter, has again been nominated for Modern Healthcare magazine’s annual 100 Most Influential People in Healthcare recognition program. If you would like to vote for Dr. Lichter https://www.surveymonkey.com/r/BP3PSYP in celebration of his many contributions to ASCO and the cancer, please do so by this Friday, June 24. And feel…

Living with Prostate Cancer Event in the Villages

  • Amanda Bridges
  • June 15, 2016
  • News
  • No Comments

On June 10th, FLASCO presented Living with Prostate Cancer, a patient educational breakfast program, in the Villages. We would like to thank Bayer Healthcare for the grant which funded the cost of the program and hand-out materials. This was an overwhelmingly successful event resulting in wonderful reviews from all in attendance. We would also like…

New $10 Million Gainesville Cancer Center Delivers Comprehensive Care in Community Setting

  • FLASCO
  • June 14, 2016
  • News
  • No Comments

Florida Cancer Specialists & The Cancer Center at North Florida Regional Healthcare Partner to Provide Broad Range of Services Under One Roof. Florida Cancer Specialists & Research Institute announced the opening of its new location, the Gainesville Cancer Center, 6420 West Newberry Road – East Wing, Suite 100. The new state-of-the-art, comprehensive cancer facility, which…

CMS Pushes Modifier -JW Requirement to 2017

CMS Pushes Modifier -JW Requirement to 2017 Source: Medicare Compliance Watch If CMS’ late April release of a change request requiring reporting of the previously optional modifier -JW (drug amount discarded/not administered to any patient) by July 1 seemed too sudden, the good news is many other providers—and the agency—agreed. Due to stakeholder concerns about…

Available Clinical Trials at UF Health Cancer Center

UF Health Cancer Center has several clinical trials in process, below please find information about four trials that are currently accepting participants: ADU-CL-11 A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer. https://clinicaltrials.gov/ct2/show/NCT02575807?term=adu-cl-11&rank=1  ARGO A Phase III Randomized Placebo-Controlled Study Evaluating…

Despite stakeholder outcry, CMS launches home health prior-authorization demo

Source: Modern Healthcare By Virgil Dickson Despite outcry from industry stakeholders, advocates and beneficiaries, the CMS is moving forward with a three-year demonstration in which beneficiaries from five states would need to get prior approval before they get home health services. The demonstration will launch in Florida, Illinois, Massachusetts, Michigan and Texas—states that are all tagged…

Flasco

2016 ASCO Annual Meeting

  • FLASCO
  • June 9, 2016
  • News
  • No Comments

FLASCO Congratulates ASCO on a very successful and extremely educational Annual Meeting. Dr. Barry Berman, FLASCO Vice President, and Dr. Michael Diaz, FLASCO President officially represented FLASCO at the 2016 ASCO Annual Meeting.  Thank you to all of the FLASCO members and corporate members who took the time to stop by the ASCO State Affiliate…

There is still time to rate First Coast Service Options’ service.

  • Amanda Bridges
  • June 7, 2016
  • News
  • No Comments

The Medicare administrative contractor (MAC) Satisfaction Indicator (MSI) is the best way to share your opinions of our service directly to CMS. This survey should only take about 10 minutes of your time and helps us understand how we can better service you. First Coast Service Options is your MAC in Florida. For a preview…

Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib

  • Amanda Bridges
  • June 7, 2016
  • News
  • No Comments

Comprehensive ELUXA trial program explores olmutinib (BI 1482694) as a monotherapy and in several combination studies Olmutinib will be studied in combination with the immuno-oncology therapy Keytruda®, second-generation TKI Gilotrif®, anti-angiogenic agents nintedanib and Avastin®, and Boehringer Ingelheim’s investigational IGF mAB BI 836845 Accelerated trial program underway with ELUXA 1 trial fully enrolled; additional Phase III trials…

New NCCN Imaging Appropriate Use Criteria Resources Help Assure Patients Receive Best Cancer Care Available

New NCCN Imaging Appropriate Use Criteria Compendium provides a single access point for all imaging recommendations within the NCCN Guidelines FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) has published the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) to support clinical decision-making around the use of imaging in patients with cancer, helping…

ASCO Value Framework Update

The American Society of Clinical Oncology (ASCO) today published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published in the Journal of Clinical Oncology, defines value as a combination of clinical benefit, side effects, and improvement in patient symptoms or quality of life in…

myriad genetics

Myriad Genetics Adds Breast Cancer Prognostic Dx to Portfolio Through Sividon Acquisition

  • FLASCO
  • June 2, 2016
  • News
  • No Comments

Myriad Genetics announced after the close of the market Tuesday the acquisition of Sividon Diagnostics in a deal that adds a breast cancer prognostic test to Myriad’s product portfolio and enhances its competitive position in oncology diagnostics. Myriad acquired Sividon for €35 million ($39 million) upfront and up to €15 million in payments based on…

Congratulations is extended to Dr. Lucio Gordan who has accepted a term on Editorial Board of Journal of Clinical Oncology – Clinical Cancer Informatics

  • FLASCO
  • May 19, 2016
  • News
  • No Comments

Florida Cancer Specialists & Research Institute (FCS) is pleased to announce that Dr. Lucio Gordan, who practices at the Gainesville Cancer Center of FCS, has accepted a new term on the Editorial Board of the Journal of Clinical Oncology Clinical Cancer Informatics (JCO CCI). The Journal of Clinical Oncology, published by the American Society of…

APP Best of ASCO Travel Awards – Apply Today!

  • FLASCO
  • May 19, 2016
  • News
  • No Comments

CALLING ALL ONCOLOGY FLASCO MEMBER ADVANCED PRACTICED PROVIDERS: Your FLASCO Board of Directors implemented an award to assist 2 Oncology PA or NP Providers to attend the Best of ASCO® for 2016.  FLASCO will award (2)two $500 Travel Awards.  The recipients will have the opportunity to attend either the 2016 Florida Hospital Best of ASCO®…

Fellow’s ASTRO Travel Award Available -Apply Today!

  • FLASCO
  • May 19, 2016
  • Fellows
  • No Comments

Oncology Focused Trainees:   Award Opportunity!  Throughout the year FLASCO offers the opportunity for FLASCO member Fellows and Residents to submit applications for Travel Awards.  If you have plans to attend the ASTRO annual meeting, please take a moment to review the attached flyer for submission requirements and directions.  You may apply for more than…

Three Florida Cancer Specialists’ Physicians Named Leukemia & Lymphoma Society’s Man/Woman of the Year

  • FLASCO
  • May 19, 2016
  • News
  • No Comments

Florida Cancer Specialists & Research Institute (FCS) is pleased to announce that Dr. Julia Cogburn, Dr. Vipul Patel and Dr. Meera Iyengar have all been named as Man/Woman of the Year 2016 by two regional Florida chapters of the Leukemia & Lymphoma Society (LLS). After a spirited fundraising campaign, these outstanding physicians and community leaders…

pfizer

Pfizer Awards More Than $1 Million In Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative

  • Amanda Bridges
  • May 13, 2016
  • News
  • No Comments

Pfizer Inc. (NYSE:PFE) today announced that it has awarded a total of more than $1 million in funding to five leading breast cancer advocacy organizations to support projects focused on metastatic breast cancer (MBC) scientific research and quality-of-life studies. The awards are part of Pfizer’s Breast Cancer: A Story Half Told initiative, aimed at uncovering…

Medivation Receives Prestigious Award From American Urological Association (AUA)

  • Amanda Bridges
  • May 13, 2016
  • News
  • No Comments

SAN FRANCISCO, CA — (Marketwired) — 05/11/16 — Medivation Inc. (NASDAQ: MDVN) announced today that it is the recipient of the 2016 Health Science Award from The American Urological Association (AUA) for outstanding support of physician and patient education in prostate cancer. The Health Science Award is presented to the company that best supports the…

New Guidelines on Bladder Cancer Management: AUA/SUO

Source: Medscape New joint guidelines on the management of bladder cancer issued by the American Urological Association (AUA) and the Society of Urologic Oncology (SUO) validate many long-standing practices used in the management of superficial bladder cancer but also affirm the real benefits associated with newer technologies to better visualize bladder tumors. Most notabable among…

CMS Proposes New Medicare Physician Payment System (Source: US Oncology)

On April 27, the Centers for Medicare and Medicaid Services released much-anticipated proposed regulations that will govern implementation of the new Medicare physician payment system that replaces the sustainable growth rate (SGR) formula repealed by Congress last year. The new system offers physicians two pathways for Medicare payment beginning in 2019: the Merit-Based Incentive Payment…

CMS requests doc input on MACRA

  • FLASCO
  • May 5, 2016
  • News
  • No Comments

Source : Modern Healthcare CMS Acting Administrator Andy Slavitt struck a strongly conciliatory tone Wednesday at the second meeting of the committee created to evaluate payment models to be used in Medicare’s new reimbursement for physicians. Physician input is critical for the success of the Medicare Access and CHIP Reauthorization Act and the CMS wants…

Florida Cancer Specialists’ Physician Named FLASCO President for Second Term

  • Amanda Bridges
  • April 26, 2016
  • News
  • No Comments

Thank you to Florida Cancer Specialists for recognizing Florida Society of Clinical Oncology’s President on his second term. We greatly appreciate Dr. Michael Diaz’s dedication and commitment to FLASCO, and would like to congratulate Dr. Diaz on a very successful first term. Dr. Michael Diaz Continues Leadership of Statewide Cancer Advocacy Organization Florida Cancer Specialists…

Three FLASCO Members Nominated for Leukemia & Lymphoma Society’s Man/Woman of the Year

  • Amanda Bridges
  • April 25, 2016
  • News
  • No Comments

Florida Cancer Specialists & Research Institute and FLASCO are pleased to announce that Dr. Julia Cogburn, Dr. Vipul Patel andDr. Meera Iyengar have been nominated by several local Florida chapters of the Leukemia & Lymphoma Society (LLS) as Man/Woman of the Year for 2016. After an intensive nominating and vetting process, these outstanding physicians and…

Fellows Travel Awards

  • Amanda Bridges
  • April 25, 2016
  • News
  • No Comments

FLASCO proudly awarded 5 Travel Awards to the following FLASCO Member Fellows. Erica Takimoto, DO, from Florida Hospital Gynecologic Oncology; Jennifer Crozier, MD, from Mayo Clinic Florida; Susmitha Apuri, MD, from Moffitt Cancer Center; Bhagirathbhai Dholaria, MBBS, from Mayo Clinic Florida; and Sharon Robertson, MD, from Moffitt Cancer Center. FLASCO supports the Oncologists of the…

FLASCO Members Visit the Hill

  • Amanda Bridges
  • April 25, 2016
  • News
  • No Comments

Yesterday, FLASCO Members, Dr. Alan Marks and Dr. Morganna Freeman, along with Matthew Martello of Johnson & Johnson, participated in Biotechnology Innovation Organization’s Fly-In Legislative Day. They were able to meet with key members of Congress and their staff. They met with Representative Kathy Castor, Representative David Jolly, Representative Daniel Webster, and Representative Alan Grayson….

FDA Clarifies Compounding Rules

The Food and Drug Administration issued three draft guidance documents on Friday that answer providers’ and pharmacists’ burning questions about drug compounding standards. The proposed rules clarify the amount of drugs that providers can compound without a prescription, set requirements for health system compounding pharmacies and clarify how large-scale compounding sites known as “outsourcing facilities” may be…

cancer experiment

Don’t forget: Contact Congress and ask them to Stop the Cancer Experiment!

The next two weeks are critical to stopping the misguided Medicare experiment on cancer care! Make your voice heard – call, email, Tweet, and send Facebook messages to your elected officials asking them to Stop the Medicare Experiment on Cancer Care. COA has set up the CancerExperiment.com website for easy advocacy action. Share the website…

New Certificate Program for Advanced Practice Providers Launched on ASCO University

  • Amanda Bridges
  • April 25, 2016
  • News
  • No Comments

Developed in partnership with professional societies that represent the full healthcare team, certificate programs for advanced practitioners who are joining oncology care settings are now available on ASCO University. These programs are designed to provide tailored education to providers with varying levels of experience, and all courses can be taken for CME, Nursing, and Pharmacy…

DISTINGUISHED SERVICE AWARD PRESENTED TO SARAH CEVALLOS: A TRUE CHAMPION AND ADVOCATE FOR PATIENT ACCESS TO CARE IN FLORIDA. 

  • FLASCO
  • April 18, 2016
  • News
  • No Comments

At the FLASCO Business of Oncology Summit on April 8th, on behalf of FLASCO, Thomas Marsland, MD presented an Distinguished Service Award to Sarah Cevallos, Chief Revenue Cycle Officer at Florida Cancer Specialists. Sarah was recognized for all of the time and talent she has dedicated to FLASCO’s Clinical Practice Commitee. She provides invaluable rapid updates…

fl cancer affiliates

Florida Cancer Affiliates First in the State Certified to Offer New Spacing Device to Benefit Prostate Cancer Patients

  • Amanda Bridges
  • March 23, 2016
  • News
  • No Comments

FCA Patients Among First in Florida Treated with SpaceOAR Rectum-Protecting Spacer Trinity, Florida (March 22, 2016) – Florida Cancer Affiliates (FCA) is helping to pioneer a new tool aimed to protect prostate cancer patients from the negative effects of radiation therapy. Recently a patient, one of the first in Florida, was injected at FCA with…

COA

300+ National & State Organizations Ask Congress: Stop the CMS Drug Payment Proposal!

  • Amanda Bridges
  • March 17, 2016
  • Advocacy
  • No Comments

This morning an unprecedented 313 national and state health care organizations, including FLASCO sent a letter to Congress expressing strong concern with the proposed CMS Medicare Part B Drug Payment Model. The organizations request that Congress ask CMS to withdraw the proposed rule. Click here to read the latest letter. The letter notes that the organizations believe…

2016 FMA Legislative Report

  • Amanda Bridges
  • March 17, 2016
  • Advocacy
  • No Comments

During the 2016 Florida Legislative Session, which ended on Friday, March 11, the FMA kept close watch on 211 bills and a host of amendments that would have affected you and your patients. Of the total 1,638 bills and proposed constitutional amendments filed for the 60-day session, the Legislature passed 272 and has sent them…

cancer care 2016

State of Cancer Care in America: 2016

  • Amanda Bridges
  • March 17, 2016
  • News
  • No Comments

The State of Cancer Care in America: 2016 report—released by the American Society of Clinical Oncology (ASCO) and published by the Journal of Oncology Practice—is the third annual report by the American Society of Clinical Oncology (ASCO) that examines trends and developments in oncology practice in the United States. The report highlights many promising cancer care developments, including…

pfizer

FDA Approves Pfizer’s Xalkori for Metastatic NSCLC

  • Amanda Bridges
  • March 17, 2016
  • Drugs
  • No Comments

On March 11, 2016, the U. S. Food and Drug Administration approved crizotinib capsules (Xalkori, Pfizer, Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. Crizotinib was first approved in 2011 for the treatment of patients whose tumors are anaplastic lymphoma kinase (ALK)-positive. The current approval was based…

FDA Approved

FDA approves first coagulation factor-albumin fusion protein to treat patients with hemophilia B

  • Amanda Bridges
  • March 17, 2016
  • Drugs
  • No Comments

The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer…

pharmacyclics

IMBRUVICA® (IBRUTINIB) APPROVED BY U.S. FDA FOR THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

  • Amanda Bridges
  • March 17, 2016
  • Drugs
  • No Comments

APPROVAL BASED ON DATA FROM THE PHASE 3 RESONATE™-2 TRIAL SHOWING AN 84% REDUCTION IN THE RISK OF PROGRESSION OR DEATH WITH IMBRUVICA COMPARED TO CHLORAMBUCIL FIRST FDA-APPROVED CHEMOTHERAPY-FREE TREATMENT OPTION FOR FIRST-LINE CLL PATIENTS THIS IS THE 5TH TREATMENT INDICATION FOR IMBRUVICA AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food…

spectrum

FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA™ (melphalan) for Injection

  • FLASCO
  • March 17, 2016
  • Drugs
  • No Comments

FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA™ (melphalan) for Injection EVOMELA Received FDA Approval for Two Indications: High-Dose Conditioning Treatment for Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT) Palliative Treatment of Patients with MM Who Cannot Take Oral Therapy EVOMELA Admixture Solution is Stable for 4 Hours at Room Temperature in Addition…

pfizer

FDA Approved New Indication for IBRANCE

  • Amanda Bridges
  • March 3, 2016
  • Drugs
  • No Comments

On February 19, 2016, the U. S. Food and Drug Administration approved palbociclib (IBRANCE Capsules, Pfizer, Inc.) in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In February 2015, FDA granted accelerated approval…

Monitoring and managing possible adverse drug reactions (ADRs) with COTELLIC + ZELBORAF1

  • Amanda Bridges
  • March 3, 2016
  • Drugs
  • No Comments

As a healthcare provider, you play an essential role in helping patients taking COTELLIC + ZELBORAF manage treatment. Genentech has created this Adverse Drug Reactions Guide as a quick reference on monitoring and managing possible serious or common ADRs.  This guide offers information on the signs and symptoms of certain possible ADRs experienced by patients…

astrazeneca

FDA Approves New Indication for FASLODEX® (fulvestrant)

  • Amanda Bridges
  • March 3, 2016
  • Drugs
  • No Comments

Approval expands use and offers additional option for women with HR+, HER2- metastatic breast cancer AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a new indication expanding the use of FASLODEX® (fulvestrant) to include use in combination with palbociclib. The combination use is for the treatment of women with hormone…

FDA Approves New Indication for Afinitor for Progressive, Nonfunctional GI and Lung NET

  • Amanda Bridges
  • March 3, 2016
  • Drugs
  • No Comments

On February 26, 2016, the U. S. Food and Drug Administration approved everolimus (Afinitor , Novartis) for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. Today’s approval was based on demonstration of improvement in progression-free survival (PFS) in…

Moffitt Researchers Develop a Novel Cancer Treatment Approach Based on Evolutionary Principals to Inhibit Chemo-Resistance, Prolong Progression-Free Survival

  • Amanda Bridges
  • March 3, 2016
  • News
  • No Comments

Despite numerous advances in oncology since the War on Cancer began, many patients develop resistance to standard therapies and eventually relapse. Moffitt Cancer Center researchers hope to improve treatment outcomes with development of a novel therapeutic strategy, called adaptive therapy, which is based on evolutionary principals and aims to keep resistant cells in check by…

Dr. Ram Tummala Joins Florida Cancer Specialists & Research Institute

  • Amanda Bridges
  • March 3, 2016
  • News
  • No Comments

Florida Cancer Specialists & Research Institute (FCSis pleased to announce that Ram Tummala, MD, has joined Florida Cancer Specialists and will be seeing patients at the FCS cancer center in The Villages East effective March 7, 2016. He will also continue to see patients at his current office in Leesburg which will add a new…

FDA Approves New Indication for Merck’s EMEND for Injection

  • FLASCO
  • February 18, 2016
  • Drugs
  • No Comments

FDA Approves New Indication for Merck’s EMEND for Injection Announcement Letter Press Release Prescribing Information Patient Product Information Merck  announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for single-dose EMEND® (fosaprepitant dimeglumine) for injection, Merck’s substance P/neurokinin-1 (NK1) receptor antagonist, in combination with other antiemetic medicines,…

Puerto Rico Business of Oncology

  • FLASCO
  • February 15, 2016
  • Events
  • No Comments

A special thanks is extended to Dr. Gerardo Colon-Otero for all of his efforts in planning and implementing a very successful Business of Oncology Summit on February 6th in San Juan, Puerto Rico.   Thanks to all who attended and participated in this event. We would like to express our sincerest gratitude to our meeting sponsors: Level 1…

FDA APPROVES EISAI’S HALAVEN® (ERIBULIN MESYLATE) INJECTION FOR THE TREATMENT OF PATIENTS WITH ADVANCED LIPOSARCOMA

  • Amanda Bridges
  • February 3, 2016
  • Drugs
  • No Comments

Eisai is pleased to announce that HALAVEN® (eribulin mesylate) Injection (0.5 mg per mL) is now approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.1 HALAVEN has been approved for the treatment of third-line metastatic breast cancer since…

Governor Rick Scott Declares February as Metastatic Breast Cancer Awareness Month

  • FLASCO
  • February 1, 2016
  • News
  • No Comments

  Governor Rick Scott Declares February as Metastatic Breast Cancer Awareness Month  TALLAHASSEE, Fla. – Metastatic breast cancer is the second leading cancer killer of women, and today Governor Rick Scott focuses attention on the complex disease by declaring February as Metastatic Breast Cancer Awareness Month in Florida. The Governor’s proclamation supports work by the Florida…

© 2021 FLASCO | Premium Website Design by The HDG